{"entity":{"id":"alice-yu","kind":"person","name":"Alice L. Yu","aka":[],"tldr":"Led the trial proving that an anti-GD2 antibody improves survival in high-risk neuroblastoma.","summary":"Alice Yu is Professor of Pediatrics at UC San Diego and an immunotherapy investigator with the Children's Oncology Group (COG). A paediatric oncologist specialising in neuroblastoma and anti-GD2 antibodies, she was study chair of COG ANBL0032, the randomised trial of ch14.18 (dinutuximab) with GM-CSF and IL-2 that established anti-GD2 immunotherapy in high-risk neuroblastoma. Her papers report the anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for neuroblastoma in the New England Journal of Medicine and the long-term follow-up of that phase III study in Clinical Cancer Research. Her work made a monoclonal antibody against GD2 part of paediatric immunotherapy.","asOf":"2026-09-08","links":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20AL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alice%20L.%20Yu"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["gd2"],"drugs":["dinutuximab"],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":["anbl0032"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Pediatrics, UC San Diego; Children's Oncology Group immunotherapy investigator","institutionId":"childrens-oncology-group","specialisms":["Neuroblastoma","Anti-GD2 antibodies","Paediatric immunotherapy"],"profiles":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20AL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alice%20L.%20Yu"}],"papers":[{"title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa0911123","doi":"10.1056/NEJMoa0911123"},{"title":"Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032","journal":"Clinical Cancer Research","year":2021,"url":"https://doi.org/10.1158/1078-0432.CCR-20-3909","doi":"10.1158/1078-0432.CCR-20-3909"}]},"route":"/people/alice-yu/","neighbours":{"cancer":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/"}],"drug":[{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/"}],"company":[{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/"}],"trial":[{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/"}],"institution":[{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/"}]}}